Publications du groupe GINECO. Année 2012

Transcription

1 Publications du groupe GINECO Année 2012

2 LE GINECO dans les publications du GINECO TAMRAD : Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol Aug 1;30(22):

3 LE GINECO dans les publications du GINECO TAXEL : Lortholary A, Hardy-Bessard AC, Bachelot T, de Rauglaudre G, Alexandre J, Bourgeois H, Jaubert D, Paraiso D, Largillier R. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer. Breast Cancer Res Treat Jan;131(1): Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E; GINECO group France. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'investigateurs Nationaux pour l'etude des Cancers Ovariens(GINECO). Ann Oncol Feb;23(2):

4 LE GINECO dans les publications du GINECO HYCAR: Kurtz JE, Freyer G, Joly F, Gladieff L, Kaminski MC, Fabbro M, Floquet A, Hardy-Bessard AC, Raban N, Ray-Coquard I, Pujade- Lauraine E; GINECO Group, France. Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial. Anticancer Res Mar;32(3): ENDORAD BIO :Trédan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray- Coquard I. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol Dec13. [Epub ahead of print] PubMed PMID:

5 LE GINECO dans les publications du GINECO Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade- Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; on behalf of the AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol Oct;23(10):

6 Sous-études CALYPSO

7 Sous-études CALYPSO Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade- Lauraine E. Health-related quality of life in recurrent platinumsensitive ovarian cancer--results from the CALYPSO trial. Ann Oncol Aug;23(8): Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials:experience of the GCIG CALYPSO trial. Br J Cancer Feb 14;106(4):633-7.

8 Sous-études CALYPSO Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinumsensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol May;23(5): Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol Oct 26. [Epub ahead of print] PubMed PMID:

9 LE GINECO dans les publications du GCIG Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol Jan 17.. Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer Jan;49(1):142-9.

10 Le GINECO à L ASCO 2012

11 LE GINECO à l ASCO 2012 Lenalidomide (REV) in asymptomatic late recurrent ovarian cancer (ROC) patients with increasing CA 125: A GINECO phase II trial. Frédéric Selle, Isabelle Ray-Coquard, Emmanuel Sevin, Véronique Mari, Dominique Berton-Rigaud, Hugues Pierre Bourgeois, Nadine Dohollou, Michel Fabbro, Anne Floquet, Anne Lesoin, Alain Lortholary, Anne-Claire Hardy-Bessard, Jean-Louis Misset, Marie- Ange Mouret-Reynier, Eric Pujade-Lauraine. Abstract #5018 Poster discussion. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace B. Vergote, Petronella Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David T. Bollag, Isabelle Ray- Coquard, AURELIA Investigators. LBA#5002 Oral session

12 LE GINECO à l ASCO 2012 Development of a geriatric vulnerability score (GVS) in elderly advanced ovarian cancer (AOC) patients (pts) treated in first line: A prospective GINECO trial. Gilles Freyer, Beatrice E. Weber, Daniela Lebrun-Jezekova, Fabien Tinquaut, Olivier Tredan, Emmanuel Sevin, Laetitia Stefani, Eric Pujade-Lauraine, Claire Falandry. Abstract #9079 Poster. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. Ignace B. Vergote, Florence Joly, Dionyssios Katsaros, Corneel Coens, Alexander Reinthaller, Marcia Hall, Christopher B. Steer, Nicoletta Colombo, Anne Lesoin, Antonio Casado, Edgar Petru, John Green, Martin Buck, Isabelle Laure Ray- Coquard, Annamaria Ferrero, Laure Favier, Nicholas Reed, Herve Curve, Antonio Jimeno, Eric Pujade-Lauraine. LBA#5000 Oral session

13 Le GINECO à L ESMO 2012

14 LE GINECO à l ESMO 2012 From a website to a national and regional reference centre network: the French experience for rare ovarian tumors. I Ray- Coquard, P Pautier, J Alexandre, M Vacher-Lavenu, M Fabbro, A Floquet, F Selle, G Ferron, N Chiannilkulchai, E Pujade-Lauraine. Abstract #993 Poster. Poveda AM, Selle F, Hilpert F, Reuss A, SavareseA, Vergote I, Witteveen P, Bamias A, Bollag D, Pujade-Lauraine E. Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): Analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial. Abstract #1254 Présentation orale

15 LE GINECO à l IGCS 2012 Kristensen G, Berton-Rigaud D, Hilpert F, Reuss A, Bover I, Raspagliesi F, D Hondt V, Witteveen P, Bamias A, Alexandre J, Harter P, Herrero A, Nyvang GB, Lesoin A, Bollag D, Pujade- Lauraine E. The effect of bevacizumab (Bev) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC) with ascites: Analysis of the AURELIA trial. Gonzalez-Martin A, Gladieff L, Tholander B, Stryakovskiy D, Gore M, Westermann A, Tjulandin S, Poveda A, Jaubert D, Bollag D, Pignata S. First efficacy results from OCTAVIA: Front-line Bevacizumab (Bev) combined with weekly paclitaxel and Q3W carboplatin for ovarian cancer (OC). LBA, Présentation orale.

16 Merci à tous les investigateurs du GINECO! Faisons aussi bien en 2013!